UPDATED RESULTS FROM A RANDOMIZED PHASE 2 DOSE-RANGING STUDY OF THE JAK2-SELECTIVE INHIBITOR SAR302503 IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS (MF)

被引：0
|
作者：
Talpaz, M. [1 ]
Jamieson, C. [2 ]
Gabrail, N. [3 ]
Lebedinsky, C. [4 ]
Gao, G. [4 ]
Patki, A. [4 ]
Lui, F. [4 ]
Tefferi, A. [5 ]
Pardanani, A. [5 ]
机构：
[1] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA
[2] Moores UCSD Canc Ctr, Dept Med, La Jolla, CA USA
[3] Gabrail Canc Ctr, Canton, OH USA
[4] Sanofi Oncol, Cambridge, MA USA
[5] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S1113
引用
收藏
页码：458 / 458
页数：1
相关论文
共 50 条
  • [1] Updated results from a randomized phase II dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with myelofibrosis (MF)
    Pardanani, Animesh Dev
    Jamieson, Catriona H. M.
    Gabrail, Nashat Y.
    Lebedinsky, Claudia
    Gao, Guozhi
    Patki, Abhay
    Liu, Feng
    Tefferi, Ayalew
    Talpaz, Moshe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
    A Pardanani
    A Tefferi
    C Jamieson
    N Y Gabrail
    C Lebedinsky
    G Gao
    F Liu
    C Xu
    H Cao
    M Talpaz
    Blood Cancer Journal, 2015, 5 : e335 - e335
  • [3] A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
    Pardanani, A.
    Tefferi, A.
    Jamieson, C.
    Gabrail, N. Y.
    Lebedinsky, C.
    Gao, G.
    Liu, F.
    Xu, C.
    Cao, H.
    Talpaz, M.
    BLOOD CANCER JOURNAL, 2015, 5 : e335 - e335
  • [4] A Phase II Randomized Dose-Ranging Study of the JAK2-Selective Inhibitor SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, or Post-Essential Thrombocythemia (ET) MF
    Talpaz, Moshe
    Jamieson, Catriona
    Gabrail, Nashat Y.
    Lebedinsky, Claudia
    Gao, Guozhi
    Liu, Feng
    Tefferi, Ayalew
    Pardanani, Animesh
    BLOOD, 2012, 120 (21)
  • [5] Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF)
    Pardanani, Animesh
    Harrison, Claire N.
    Cortes, Jorge E.
    Cervantes, Francisco
    Mesa, Ruben A.
    Milligan, Donald
    Masszi, Tamas
    Mishchenko, Elena
    Jourdan, Eric
    Vannucchi, Alessandro M.
    Drummond, Mark
    Jurgutis, Mindaugas
    Kuliczkowski, Kazimierz
    Gheorghita, Emanuil
    Passamonti, Francesco
    Neumann, Frank
    Gao, Guozhi
    Tefferi, Ayalew
    BLOOD, 2013, 122 (21)
  • [6] MODULATION OF PLASMA CYTOKINES AND ITS ASSOCIATION WITH CLINICAL RESPONSE TO TREATMENT WITH THE JAK2-SELECTIVE INHIBITOR SAR302503 IN A PHASE 2 STUDY OF PATIENTS WITH MYELOFIBROSIS (MF)
    Talpaz, M.
    Jamieson, C.
    Gabrail, N.
    Lebedinsky, C.
    Liu, F.
    Cao, H.
    Tefferi, A.
    Pardanani, A.
    HAEMATOLOGICA, 2013, 98 : 117 - 117
  • [7] Modulation of plasma cytokines and its association with clinical response to treatment with the JAK2-selective inhibitor SAR302503 in myelofibrosis (MF)
    Talpaz, Moshe
    Jamieson, Catriona H. M.
    Gabrail, Nashat Y.
    Lebedinsky, Claudia
    Liu, Feng
    Cao, Hui
    Tefferi, Ayalew
    Pardanani, Animesh Dev
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis
    Jamieson, Catriona H. M.
    Hasserjian, Robert P.
    Gotlib, Jason
    Cortes, Jorge E.
    Stone, Richard M.
    Talpaz, Moshe
    Thiele, Juergen
    Rodig, Scott
    Patki, Abhay
    Wu, Kaida
    Wu, Jingyang
    Pozdnyakova, Olga
    BLOOD, 2013, 122 (21)
  • [9] LONG-TERM FOLLOW UP OF A PHASE 1/2 STUDY OF SAR302503, AN ORAL JAK2 SELECTIVE INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF)
    Gotlib, J.
    Pardanani, A.
    Jamieson, C.
    Cortes, J.
    Talpaz, M.
    Stone, R.
    Gao, G.
    Zhang, J.
    Neumann, F.
    Lebedinsky, C.
    Tefferi, A.
    HAEMATOLOGICA, 2012, 97 : 145 - 145
  • [10] Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial
    Pardanani, Animesh
    Tefferi, Ayalew
    Masszi, Tamas
    Mishchenko, Elena
    Drummond, Mark W.
    Jourdan, Eric
    Vannucchi, Alessandro M.
    Jurgutis, Mindaugas
    Ribrag, Vincent
    Rambaldi, Alessandro
    Koh, Liang Piu
    Rose, Shelonitda
    Zhang, Jun
    Harrison, Claire
    BLOOD, 2020, 136
12345